OXIDATIVE STRESS AND BRAIN AGING

氧化应激和大脑老化

基本信息

项目摘要

The ability of reactive oxygen species (ROS) to produce dysfunctional macromolecules is thought to play a significant role in brain aging and in neurodegenerative diseases. However, it is also well established that ROS serve as important signaling molecules involved in cellular processes that underlie different cognitive functions. In the current application, it is hypothesized that age-dependent increases in ROS may cause age- associated cognitive or motor impairment by (i) promoting deleterious accumulation of oxidative damage to specific mitochondrial proteins, (ii)causing a decrease in efficiency of ROS-mediated signaling and/or(iii) initiating compensatory shifts in signaling mechanisms underlying brain processes. Under Aim 1 of this application, we will identify proteins in mitochondria from different brain regions that are associated with age- related increases in carbonyls, in aged mice with and without cognitive or motor impairments. The functional significance of these impairment-associated oxidized proteins will be addressed further under Aim 2, in which it is proposed to determine the correlation between impaired bioenergetic activity of oxidized proteins and age-related behavioral dysfunction. Aim 3 of this application will assess whether or not the age-related increase in "unregulated ROS" contributes to impairment of synaptic plasticity and memory function, and assess whether or not this contribution is age-dependent. Aim 4 of the application is to determine if behavioral impairments associatedwith ROS can be reversed by experimental interventions that produce reductive shifts in the redox state of glutathione, or promote recovery of bioenergetic functions of specific oxidized proteins. The Aim 4 studies will also address whether or not the ability of interventions to reverse age-related impairments is age-dependent. The results of these studies should refute or validate the idea that oxidative damage to specific mitochondrial proteins is a factor in age-related decrements in cognitive or psychomotor performance, and may identify specific molecules that should be targeted by anti-aging interventions. These studies will also address the hypothesis that increases in unregulated ROS directly impair cognition during aging and promote relatively non-reversible derangement of underlying signaling processes. Finally, these studies will identify periods of senescence for which antioxidative treatment of cognitive decline is most likely to be successful.
活性氧 (ROS) 产生功能失调的大分子的能力被认为在 在大脑衰老和神经退行性疾病中发挥着重要作用。然而,也已经确定的是 ROS 作为重要的信号分子参与不同认知基础的细胞过程 功能。在当前的应用中,假设 ROS 的年龄依赖性增加可能会导致年龄- 相关的认知或运动障碍,通过(i)促进氧化损伤的有害积累 特定线粒体蛋白,(ii) 导致 ROS 介导的信号传导效率降低和/或 (iii) 启动大脑过程中信号机制的补偿性转变。在本目标 1 下 应用程序,我们将识别来自不同大脑区域的线粒体中与年龄相关的蛋白质 在有或没有认知或运动障碍的老年小鼠中,羰基的相关增加。功能性的 这些与损伤相关的氧化蛋白的重要性将在目标 2 下进一步讨论, 建议确定氧化蛋白质的生物能活性受损之间的相关性 以及与年龄相关的行为功能障碍。本申请的目标 3 将评估是否与年龄相关 “不受调节的活性氧”的增加会导致突触可塑性和记忆功能受损,并且 评估这种贡献是否与年龄有关。该应用程序的目标 4 是确定是否 与 ROS 相关的行为障碍可以通过产生的实验干预来逆转 谷胱甘肽氧化还原态的还原转变,或促进特定生物能功能的恢复 氧化蛋白质。目标 4 研究还将探讨干预措施是否能够逆转 与年龄相关的损伤与年龄有关。这些研究的结果应该反驳或验证这个想法 对特定线粒体蛋白的氧化损伤是与年龄相关的认知或认知能力下降的一个因素 精神运动表现,并可以识别抗衰老应针对的特定分子 干预措施。这些研究还将解决不受调节的 ROS 直接增加的假设 在衰老过程中损害认知并促进潜在信号传导相对不可逆的紊乱 流程。最后,这些研究将确定抗氧化治疗的衰老时期 认知能力下降最有可能成功。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MICHAEL J. FORSTER其他文献

MICHAEL J. FORSTER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MICHAEL J. FORSTER', 18)}}的其他基金

Dietary targeting of dihydrolipoamide dehydrogenase for stroke tolerance
二氢硫辛酰胺脱氢酶的饮食靶向治疗中风耐受性
  • 批准号:
    8620729
  • 财政年份:
    2013
  • 资助金额:
    $ 25.37万
  • 项目类别:
Dietary targeting of dihydrolipoamide dehydrogenase for stroke tolerance
二氢硫辛酰胺脱氢酶的饮食靶向治疗中风耐受性
  • 批准号:
    9240669
  • 财政年份:
    2013
  • 资助金额:
    $ 25.37万
  • 项目类别:
Dietary targeting of dihydrolipoamide dehydrogenase for stroke tolerance
二氢硫辛酰胺脱氢酶的饮食靶向治疗中风耐受性
  • 批准号:
    9021008
  • 财政年份:
    2013
  • 资助金额:
    $ 25.37万
  • 项目类别:
Dietary targeting of dihydrolipoamide dehydrogenase for stroke tolerance
二氢硫辛酰胺脱氢酶的饮食靶向治疗中风耐受性
  • 批准号:
    8506257
  • 财政年份:
    2013
  • 资助金额:
    $ 25.37万
  • 项目类别:
Animal Core
动物核心
  • 批准号:
    9210037
  • 财政年份:
    2007
  • 资助金额:
    $ 25.37万
  • 项目类别:
Animal Core
动物核心
  • 批准号:
    8974804
  • 财政年份:
    2007
  • 资助金额:
    $ 25.37万
  • 项目类别:
Animal Core
动物核心
  • 批准号:
    8589550
  • 财政年份:
    2007
  • 资助金额:
    $ 25.37万
  • 项目类别:
Animal Core
动物核心
  • 批准号:
    8436391
  • 财政年份:
    2007
  • 资助金额:
    $ 25.37万
  • 项目类别:
Animal Core
动物核心
  • 批准号:
    8776901
  • 财政年份:
    2007
  • 资助金额:
    $ 25.37万
  • 项目类别:
Brain aging and antioxidant supplementation
大脑老化和抗氧化剂补充
  • 批准号:
    7847476
  • 财政年份:
    2006
  • 资助金额:
    $ 25.37万
  • 项目类别:

相似海外基金

Novel Prostate cancer therapy based on m-aconitase inhibition
基于 m-乌头酸酶抑制的新型前列腺癌疗法
  • 批准号:
    10435673
  • 财政年份:
    2022
  • 资助金额:
    $ 25.37万
  • 项目类别:
Fumarates for Alcoholic Liver Disease
富马酸盐治疗酒精性肝病
  • 批准号:
    10452220
  • 财政年份:
    2022
  • 资助金额:
    $ 25.37万
  • 项目类别:
Fumarates for Alcoholic Liver Disease
富马酸盐治疗酒精性肝病
  • 批准号:
    10700042
  • 财政年份:
    2022
  • 资助金额:
    $ 25.37万
  • 项目类别:
Novel Prostate cancer therapy based on m-aconitase inhibition
基于 m-乌头酸酶抑制的新型前列腺癌疗法
  • 批准号:
    10580844
  • 财政年份:
    2022
  • 资助金额:
    $ 25.37万
  • 项目类别:
Fumarates for Alcoholic Liver Disease
富马酸盐治疗酒精性肝病
  • 批准号:
    10700042
  • 财政年份:
    2022
  • 资助金额:
    $ 25.37万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了